Intellia Therapeutics
NTLA
295 hedge funds and large institutions have $720M invested in Intellia Therapeutics in 2025 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 95 increasing their positions, 96 reducing their positions, and 46 closing their positions.
9% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $6.43M
9% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 46
0.36% more ownership
Funds ownership: 97.48% → 97.84% (+0.36%)
0% more funds holding
Funds holding: 294 → 295 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 96
38% less capital invested
Capital invested by funds: $1.16B → $720M (-$438M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$38.2M |
| 2 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
+$10.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.68M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.79M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$3.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.16M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.99M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.02M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.21M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$6.12M |
NTLA Hedge Fund Activity: Q1 2025 in Review
295 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2025, worth a combined $720M — down 38% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new NTLA positions and 46 closed out — a net gain of 4 holders — while 95 added to existing stakes and 96 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $38.2M. The largest seller was Wellington Management Group, exiting entirely with an estimated $8.16M sold.
- 295 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2025, up from 294 in Q4 2024.
- Funds reported $720M of Intellia Therapeutics stock for Q1 2025, down 38% quarter-over-quarter.
- 50 funds opened new Intellia Therapeutics positions in Q1 2025 and 46 closed out, a net change of +4 holders.
- The largest Intellia Therapeutics buyer in Q1 2025 was Capital International Investors, an estimated $38.2M added.
- The largest Intellia Therapeutics seller in Q1 2025 was Wellington Management Group, an estimated $8.16M sold.
Based on aggregated 13F filings for Q1 2025.